Want to see HK:2496 full AI Analyst Report?
Top Page
Wuhan YZY Biopharma Co., Ltd. Class H
(2496)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$4.00
▲(21.21% Upside)
Action:Reiterated
Date:10/15/26
The score is held down primarily by weak financial performance—sharp 2025 revenue and margin deterioration, persistent large losses, and negative equity indicating elevated solvency/financing risk—partly offset by a meaningful improvement in cash burn. Technicals are mixed (short-term strength but longer-term weakness), and valuation is difficult to support due to ongoing losses and no dividend yield data.
Positive Factors
Improved Cash Burn
The sharp reduction in operating and free-cash-flow burn indicates materially tighter spending or working-capital relief in 2025. Although cash generation remains negative, this improvement could extend the company’s operating runway and reduce near-term financing pressure if sustained.
Negative Factors
Revenue Contraction
A revenue decline of this magnitude weakens the company’s commercial scale and reduces the base available to absorb research, development, and operating costs. Unless the contraction reverses, it can limit investment capacity, delay operating leverage, and prolong the path to sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Burn
The sharp reduction in operating and free-cash-flow burn indicates materially tighter spending or working-capital relief in 2025. Although cash generation remains negative, this improvement could extend the company’s operating runway and reduce near-term financing pressure if sustained.
Read all positive factors
Wuhan YZY Biopharma Co., Ltd. Class H (2496) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.05B
Dividend YieldN/A
Average Volume (3M)76.31K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth-55.22%
EPS Growth57.76%
CountryHK
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding179,479,110
10 Day Avg. Volume140
30 Day Avg. Volume76,306
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)-26.32
Price to Sales (P/S)21.44
P/FCF Ratio-62.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wuhan YZY Biopharma Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic co...
Wuhan YZY Biopharma Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.68M | 65.13M | 107.81M | 11.92M | 2.28M | 12.18M |
| Gross Profit | 34.53M | 6.17M | 85.07M | 11.92M | 2.28M | 12.18M |
| EBITDA | -39.37M | -83.49M | -86.95M | -157.46M | -168.63M | -124.61M |
| Net Income | -47.72M | -82.54M | -97.60M | -190.98M | -188.87M | -148.52M |
Balance Sheet | ||||||
| Total Assets | 177.01M | 175.08M | 267.84M | 301.62M | 302.84M | 200.16M |
| Cash, Cash Equivalents and Short-Term Investments | 75.98M | 100.11M | 126.28M | 196.68M | 200.52M | 83.71M |
| Total Debt | 138.62M | 127.81M | 127.35M | 90.11M | 76.67M | 28.48M |
| Total Liabilities | 235.55M | 228.13M | 237.31M | 173.97M | 146.96M | 56.99M |
| Stockholders Equity | -58.55M | -53.05M | 30.54M | 127.65M | 155.88M | 143.16M |
Cash Flow | ||||||
| Free Cash Flow | -86.76M | -22.46M | -102.22M | -187.95M | -156.40M | -82.10M |
| Operating Cash Flow | -80.39M | -21.57M | -100.72M | -186.02M | -155.16M | -80.55M |
| Investing Cash Flow | -6.25M | -130.00K | -4.67M | 54.81M | 5.80M | -19.93M |
| Financing Cash Flow | -33.03M | -4.68M | 33.02M | 176.29M | 241.33M | 81.03M |
Wuhan YZY Biopharma Co., Ltd. Class H Technical Analysis
Positive
3.30
Price Trends
3.32
Positive
3.56
Positive
4.70
Negative
Market Momentum
0.18
Negative
72.43
Negative
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2496, the sentiment is Positive. The current price of 3.3 is below the 20-day moving average (MA) of 3.35, below the 50-day MA of 3.32, and below the 200-day MA of 4.70, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 72.43 is Negative, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2496.
Wuhan YZY Biopharma Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$673.84M | -3.12 | -30.93% | ― | -17.22% | -6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$1.79B | 17.80 | 48.25% | ― | 88.38% | ― | |
44 Neutral | HK$1.05B | -13.87 | 85.52% | ― | -55.22% | 57.76% | |
44 Neutral | HK$708.65M | -3.48 | -7.32% | ― | ― | 51.71% | |
43 Neutral | HK$327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% | |
42 Neutral | HK$970.43M | -8.76 | -39.21% | ― | ― | ― |
* Healthcare Sector Average
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
4.00
-3.01
-42.94%
HK:2137
Brii Biosciences Limited
0.98
-0.84
-46.12%
HK:1244
3D Medicines, Inc.
2.61
-3.70
-58.64%
HK:2181
Mabpharm Limited
0.44
-0.09
-16.35%
HK:6628
Transcenta Holding Limited
0.74
-2.34
-76.06%
HK:2898
Sunho Biologics,Inc.
6.39
-1.61
-20.13%
Wuhan YZY Biopharma Co., Ltd. Class H Corporate Events
Wuhan YZY Biopharma Seeks Shareholder Nod for Insider Share Subscription and Whitewash Waiver
Oct 30, 2026
Wuhan YZY Biopharma has called an extraordinary general meeting for 17 November 2026 in Wuhan to seek shareholder approval for a major share subscription by three executive-linked subscribers, including chairman and CEO Dr. Zhou Pengfei, involving...
Wuhan YZY Biopharma Sets November EGM to Approve Capital and Governance Changes
Oct 28, 2026
Wuhan YZY Biopharma has scheduled an extraordinary general meeting for 17 November 2026 in Wuhan to consider matters including a share subscription, a specific mandate, a whitewash waiver and proposed amendments to its articles of association. The...
YZY Biopharma Doses First Patient in Phase I Trial of Emicizumab Biosimilar Y225
Oct 16, 2026
Wuhan YZY Biopharma Co., Ltd., a Chinese biopharmaceutical company specializing in antibody drugs and biosimilars, is advancing therapies aimed at improving long-term care for chronic and rare diseases, including hemophilia A. Through proprietary ...
Wuhan YZY Biopharma Seeks Extension for Key Share Subscription Circular
Sep 30, 2026
Wuhan YZY Biopharma Co., Ltd. has announced a delay in sending a circular to shareholders regarding a proposed connected share subscription, a specific mandate for issuing new domestic shares, a whitewash waiver, and amendments to its articles of ...
Wuhan YZY Biopharma Reshapes Company Secretary and Process Agent Roles
Sep 30, 2026
Wuhan YZY Biopharma announced that the Hong Kong Stock Exchange has confirmed current joint company secretary Mr. Zheng Jianhua is qualified to serve as the company secretary once a prior waiver expires on September 24, 2026. As a result, joint co...
Wuhan YZY Biopharma Plans Major Connected Share Issue Requiring Whitewash Waiver
Sep 9, 2026
Wuhan YZY Biopharma plans to issue 35,592,400 new domestic shares at RMB2.43 per share under a specific mandate, raising estimated net proceeds of about RMB83 million. The new shares represent roughly 247.68% of existing domestic shares and will s...
Wuhan YZY Biopharma Halts Hong Kong Trading Ahead of Takeover-Related Announcement
Aug 31, 2026
Wuhan YZY Biopharma Co., Ltd. has requested a halt in trading of its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on 31 August 2026. The suspension precedes the release of an announcement under Hong Kong’s Codes on Takeov...
Wuhan YZY Biopharma Narrows Interim Loss but Net Liabilities Deepen
Aug 28, 2026
Wuhan YZY Biopharma reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB33.1 million, down from RMB37.2 million a year earlier, but a sharp improvement in gross profit to RMB25.3 million from RMB7.7 mil...
Wuhan YZY Biopharma Sets Board Meeting to Approve Interim 2026 Results
Aug 18, 2026
Wuhan YZY Biopharma Co., Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The meeting will also address other corporate ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.